Drug Profile
Citatuzumab bogatox - Carisma Therapeutics
Alternative Names: VB6-845; VB6-845dLatest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator Viventia Biotech
- Developer Carisma Therapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Recombinant fusion proteins
- Mechanism of Action Protein synthesis inhibitors; Ribosomal protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 07 Mar 2023 Sesen Bio has merged with Carisma Therapeutics to form Carisma Therapeutics
- 28 Nov 2019 No recent reports of development identified for phase-I development in Solid-tumours in Georgia (IV, Infusion)
- 28 Nov 2019 No recent reports of development identified for phase-I development in Solid-tumours in Russia (IV, Infusion)